Narrow search
Showing 1 - 10 of 3,277
Cover Image
Dynamic mergers effects on R&D investments and drug development across research phases in the pharmaceutical industry
Siebert, Ralph; Tian, Zhili - 2020
sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the … effects of M&As on firms' post-merger R&D investments and drug development capabilities across drug development phases. This … study builds on a novel database that enables us to evaluate the post-merger effect at the research project level and across …
Persistent link: https://www.econbiz.de/10012219372
Cover Image
Industrial and organizational mutations in the medical and pharmaceutical sectors impulsed by open innovation during the pandemic
Adatto, Laurent; Aouinait, Camille; Son Thi Kim Le; … - In: Proceedings of the ENTRENOVA - ENTerprise REsearch … 8 (2022) 1, pp. 421-434
The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate...
Persistent link: https://www.econbiz.de/10014308369
Cover Image
Innovation Consolidation
Lee, Peter - 2021
efficiencies of size, and significant merger and acquisition activity. It also argues that several common “fragmentation drivers …
Persistent link: https://www.econbiz.de/10013213690
Cover Image
What drives innovation? : lessons from COVID-19 R&D
Agarwal, Ruchir; Gaulé, Patrick - 2021
To examine the drivers of innovation, this paper studies the global R&D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R&D activity - measured by clinical trials - typically follows the 'law of diminishing efforts': i.e. the elasticity of R&D...
Persistent link: https://www.econbiz.de/10012430944
Cover Image
Setting the "right" goal : post M&A innovation performance and goal orientation
Doan Thu Trang - In: Verslas : teorija ir praktika : Vilniaus Gedimino … 21 (2020) 2, pp. 555-565
Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes....
Persistent link: https://www.econbiz.de/10012502063
Cover Image
How the Sunk Costs of Incumbents Make Entrants Important for Innovation : A Model and Implications for Policy
Rtischev, Dimitry - 2016
The paper clarifies how sunk costs can lead a rational incumbent to innovate less than an entrant. It also demonstrates that competition among incumbents yields less adoption of new and more efficient production technology than competition which includes entrants. The results suggest that policy...
Persistent link: https://www.econbiz.de/10012996869
Cover Image
How does basic research improve innovation performance in the world's major pharmaceutical firms?
Leten, Bart; Kelchtermans, Stijn; Belderbos, René - In: Industry and innovation 29 (2022) 3, pp. 396-424
Persistent link: https://www.econbiz.de/10013170079
Cover Image
Developing a system dynamic model for product life cycle management of generic pharmaceutical products : its relation with open innovation
Mousavi, Atefeh; Mohammadzadeh, Mehdi; Zare, Hossein - In: Journal of open innovation : technology, market, and … 8 (2022) 1, pp. 1-19
“reference mode”, determined the causal loop of the pharmaceuticals phase of PLC based on both an in-depth literature review and …
Persistent link: https://www.econbiz.de/10012801597
Cover Image
Product innovation success based on cancer research in the pharmaceutical industry : co-publication networks and the effects of partners
McKelvey, Maureen D.; Rake, Bastian - In: Industry and innovation 23 (2016) 5, pp. 383-406
Persistent link: https://www.econbiz.de/10011523939
Cover Image
Private versus social incentives for pharmaceutical innovation
González, Paula; Macho-Stadler, Inés; … - 2015
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575